Highlight report by Ghallab, Ahmed
EXCLI Journal 2018;17:1191-1193 – ISSN 1611-2156 
Received: December 17, 2018, accepted: December 18, 2018, published: December 19, 2018 
 
 
1191 
Guest editorial: 
HIGHLIGHT REPORT:  
NECROSIS-APOPTOSIS CONUNDRUM OF HEPATOCYTES:  
MODE OF HEPATOCYTE DEATH AFTER ACETAMINOPHEN  
INTOXICATION 
 
Ahmed Ghallab 
 
Forensic Medicine and Toxicology Department, Faculty of Veterinary Medicine, 
South Valley University, Qena, Egypt, E-mail: ghallab@vet.svu.edu.eg 
 
http://dx.doi.org/10.17179/excli2018-2013 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(http://creativecommons.org/licenses/by/4.0/). 
 
 
 
Recently, Huo Du from Hartmut 
Jaesches’s group at University of Kansas pub-
lished an outstanding study about the mode of 
hepatocyte killing by acetaminophen and 
demonstrate that the typical necrotic cell 
death may switch to secondary apoptosis after 
specific interventions (Du et al., 2018). 
Acetaminophen (APAP) is responsible for 
more than 70.000 hospitalizations per year 
and approximately 50 % of acute liver failure 
cases (Budnitz et al., 2011; Manthripragada et 
al., 2011). Cell killing by APAP is a conse-
quence of cytochrome P450-mediated for-
mation of the reactive N-acetyl-p-benzoqui-
none imine (NAPQI) that binds to proteins 
and glutathione (Mc Gill and Jaeschke, 2013, 
2015; Nelson, 1989; Xie et al., 2015). It is 
well accepted that APAP kills hepatocytes 
predominantly by necrosis rather than by 
apoptosis (Bajt et al., 2004; Gujral et al., 
2002; Jaeschke et al., 2011; McGill et al., 
2011). This phenomenon has been observed 
in vivo and in vitro. The preference for necro-
sis remains difficult to understand, because 
some mechanisms considered specific for 
apoptosis are still induced by APAP, such as 
mitochondrial translocation of bax and re-
lease of cytochrome C, but nevertheless do 
not lead to apoptotic phenotype (Du et al. 
2016; Adams et al., 2001; Knight and Jaes-
chke, 2002; Bajt et al., 2008). 
In their present study, Du and colleagues 
came much closer to an explanation of this co-
nundrum (Du et al., 2018). They used the mi-
tochondria-targeted superoxide dismutase mi-
metic Mito-tempo in mice intoxicated with a 
hepatotoxic dose of 300 mg/kg APAP. As ex-
pected, Mito-tempo reduced APAP induced 
necrosis and led to an overall protection 
against hepatotoxicity. However, some hepa-
tocytes switched to a clearly apoptotic pheno-
type as evidenced by morphology, TUNEL 
positivity and caspase activation, which was 
not observed after APAP intoxication without 
Mito-tempo administration (Du et al., 2018). 
In an elegant series of experiments using 
RIP3 knockout mice and decreasing RIP3 
protein levels by a RIP3-morpholino, the au-
thors demonstrate that the effect of Mito-
tempo is due to inhibition of RIP3. In conclu-
sion, the necrosis-apoptosis conundrum of 
hepatocytes is due to RIP3 kinase, which tips 
the balance to necrosis, while its inhibition 
switches cell death to necrosis. 
Currently, hepatotoxicity is a major re-
search focus, because drug induced liver in-
jury represents a frequent cause of drug with-
drawal from the market (Godoy et al., 2013, 
2016; Hewitt et al., 2007; Reif et al., 2017). 
Numerous studies aim at a better understand-
ing of the molecular and pathophysiological 
mechanisms of hepatotoxicity (Hassan, 2016; 
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Stöber, 2016; Sezgin et al., 2018; Jansen et 
al., 2017; Vartak et al., 2016; Ghallab et al., 
2016; Bolt, 2017; Schenk et al., 2017; Thiel et 
al., 2015; Hammad et al., 2014). A frequently 
applied strategy in toxicology is to construct 
‘adverse outcome pathways’ (Leist et al., 
2017; Rodrigues et al., 2018) aiming for pos-
sibilities to study hepatoxicity in vitro and in 
silico (Ghallab, 2017; Hammad, 2013; Grin-
berg et al., 2014, 2018; Gu et al., 2018; Shinde 
et al., 2015; Frey et al., 2014). 
However, this strategy is hampered by the 
fact that so many aspects of hepatotoxicity in 
vivo remain elusive, even for a compound as 
intensively studied as APAP. In conclusion, 
Huo Du and colleagues are to be congratu-
lated that they unraveled a mystery that con-
fused toxicologists since decades. 
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